Response by Yang et al. to Letter Regarding Article “Type 2 Inflammation: A Potential Clinical Link Between Asthma and Cardiovascular Diseases”

References

[1] Jawed H, Mukhi R, Saleem MS, Saeed MH. Letter by Jawed et al. Regarding article “Type 2 inflammation: a potential clinical link between asthma and cardiovascular diseases. Cardiovasc Innov Appl. 2026. Vol. 11(1):1-2

[2] Yang Z, Ge Y, Zuo R, Wang J, Wang W, Shao C, et al.. Type 2 inflammation: a potential clinical link between asthma and cardiovascular diseases. Cardiovasc Innov Appl. 2025. Vol. 10(1):e968

[3] Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. Inflammation and cardiovascular disease: 2025 ACC Scientific Statement: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2025. Vol. 85(10):1234-56

[4] Zheng WC, Chan W, Dart A, Shaw JA. Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease. Eur Heart J Cardiovasc Pharmacother. 2024. Vol. 10(1):53-67

[5] World Health Organization. Cardiovascular diseases (CVDs). Geneva: WHO. 2025 cited 2025 Dec 27

[6] Berkan K, Tan T, Van der Heijden C, Andersen LB, MĂĽller S, Sato R, et al.. A multi-centre, randomized trial of a novel oral PCSK9 inhibitor in patients with familial hypercholesterolaemiaPresented at ESC 2025, 29th August, Madrid, Spain;

[7] Kausik R, Johnson M, Rossi G, Chen L, Park S, Fischer A, et al..Artificial intelligence-guided risk stratification for major adverse cardiac events in a primary care population: the PREVENT-AI studyPresented at ESC 2025, 29th August, Madrid, Spain;

[8] Figtree GA, Vernon ST, Harmer JA, Gray MP, Arnott C, Bachour E, et al.. Clinical pathway for coronary atherosclerosis in patients without conventional modifiable risk factors: JACC state-of-the-art review. J Am Coll Cardiol. 2023. Vol. 82(13):1343-59